PTCT

Over the past six months, PTC Therapeutics' stock has experienced significant activity, increasing by 7.73% in the past month and 80.45% over the last 12 months, trading at $64.49 as of May 8, 2026. Key events include strong Q1 2026 financial results with raised guidance driven by Sephience, positive clinical data from the PIVOT-HD extension study of votoplam for Huntington's disease, and generic erosion of Emflaza. Q1 2025 saw exceptionally high revenue and net income, skewing trailing twelve-month profitability.